Clinical trials: Solid Cancer
Refractory Solid Tumors
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
- Trial name
- NCT06006273
- Testing
- Eribulin, Irinotecan, Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Childhood Solid Tumor, Protocol Specific
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of bevacizumab in treating young patients with refractory solid tumors.
- Trial name
- NCT00085111
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Cancer
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum
A phase I study of Intraperitoneal Radioimmunotherapy with 131 I-omburtamab in patients >1 year of age with desmoplastic small round cell tumors and other solid tumors involving the peritoneum.
- Trial name
- NCT01099644
- Testing
- 131 I-8H9
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Y-mAbs Therapeutics
Advanced Solid Tumors
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates.
- Trial name
- NCT01178411
- Testing
- Tivantinib, Anti-Cancer Combination Therapy
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Refractory Solid Tumors in Children
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
This phase I study is designed to determine the maximum tolerated dose of Irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of Vincristine, Temozolomide and Bevacizumab (VIT-B) in patients with…
- Trial name
- VIT-B (NCT00993044)
- Testing
- Irinotecan, Vincristine, Temozolomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Los Angeles
Sarcoma, Ewing, Rhabdomyosarcoma
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Background: The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma.
- Trial name
- NCT04890093
- Testing
- PEN-866, Vincristine, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
The goal of this clinical research study is to find out if giving azacitidine with valproic acid plus carboplatin can help control advanced cancer. The safety of this treatment will be studied as well.
- Trial name
- NCT00529022
- Testing
- Azacitidine, Valproic Acid, Carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial
This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities.
- Trial name
- NCT06314672
- Testing
- Accrual, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Modern frontline therapy for patients with hematologic malignancies is based on intensive administration of multiple drugs. In patients with relapsed disease, response to the same drugs is generally poor, and dosages cannot be…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma
- Trial name
- NCT00640796
- Testing
- Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- St. Jude Children's Research Hospital
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents.
- Trial name
- NCT06513962
- Testing
- Best Practice, Biospecimen Collection, Electronic Health Record Review
- Where
- 206 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Children's Oncology Group
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
This clinical trial studies sirolimus in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Trial name
- NCT01791088
- Testing
- sirolimus, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Chicago
Pulmonary Nodules
A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors
Because the management of children with solid tumors hinges on the extent of disease, it is crucial to identify metastatic sites. Helical chest computed tomography (CT) is the standard method of excluding pulmonary metastases.
- Trial name
- NCT00629460
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- St. Jude Children's Research Hospital
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Provide expanded access of cemiplimab in patients with solid tumors
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06132191
- Testing
- Cemiplimab
- Sponsor
- Regeneron Pharmaceuticals
Pediatric Solid Tumor
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Irinotecan is a commonly used salvage chemotherapy drug for children with relapsed and refractory solid tumors. Common dose-limiting toxicities of irinotecan include abdominal pain and diarrhea.
- Trial name
- NCT06760117
- Testing
- Irinotecan (CPT-11), Temozolomide (TMZ), Vincristine
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma
- Trial name
- NCT01772771
- Testing
- Biospecimen Collection, Genetic Testing, Medical Chart Review
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors…
- Trial name
- NCT03611595
- Testing
- Cabozantinib, 13-cis-retinoic acid
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Peter Zage
Leukemia, Lymphoma
Quality of Life in Children Treated for Cancer
RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for children with cancer. PURPOSE: This randomized clinical trial is studying the quality of life in children treated for cancer.
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00005881
- Testing
- Quality of Life Forms
- Where
- 17 sites in United States
- Volunteers
- 538 people
- Sponsor
- Children's Oncology Group
Solid Tumor, Brain Tumor
Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant
Autologous stem cell rescue is an established therapy in high risk neuroblastoma and relapsed Hodgkin's lymphoma and an experimental therapy in some other solid and brain tumors to facilitate the use of very intense chemotherapy…
- Conditions
- Solid Tumor, Brain Tumor, Lymphoma
- Trial name
- IROPAST (NCT01540175)
- Testing
- Blood samples obtained
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- St. Jude Children's Research Hospital
Solid Tumor, Urethral Cancer
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or…
- Trial name
- NCT00479128
- Testing
- Bortezomib, Gemcitabine, Doxorubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
This phase I trial is studying the side effects and best dose of bevacizumab and cediranib maleate in treating patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma or anaplastic…
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00458731
- Testing
- bevacizumab, cediranib maleate
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)